Back to Research Hub
Summit Therapeutics Inc.
SMMT
$14.29+0.18 (+1.28%)
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI).
StreetsValue research for Summit Therapeutics Inc. (SMMT)
Members get the full report for Summit Therapeutics Inc.: a fair value estimate and valuation analysis, economic moat rating, growth and profitability factor grades, a bull and bear investment thesis, analyst price targets, insider and congressional trading activity, and which super investors own the stock.